Recruitment status
- Recruiting31
- Completed26
- Active, not recruiting15
- Not yet recruiting11
- Unknown status7
- Withdrawn5
- Terminated2
- Enrolling by invitation1
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Depression trial landscape
Psilocybin Clinical Trials for Depression
Review registry-listed psilocybin studies involving depressive disorders, from major depression and treatment-resistant depression to related clinical definitions used by study teams.
Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.
98matching trials
31currently recruiting
288registry-listed sites
Registry facts checkedAug 10, 2026 01:26 UTC
Live registry synthesis
Status, geography, and study phase
Condition terminology is not uniform across protocols. This collection therefore groups explicit depression-related registry labels while preserving every trial’s original condition wording in the records below.
Leading countries
- United States54
- Canada18
- United Kingdom6
- France5
- Czechia5
- Netherlands4
- Ireland4
- Denmark3
Trial phases
- Phase 268
- Phase 114
- Phase 310
- Not applicable5
- Early Phase 11
Server-rendered source index
98 matching registry records
Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.
RecruitingNCT06455293
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Joshua Woolley, MD, PhD
- Conditions
- Parkinson Disease · Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2026-08-07
Active, not recruitingNCT06731621
Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism
Centre for Addiction and Mental Health
- Conditions
- Treatment Resistant Depression · Autism Spectrum Disorder
- Phase
- Phase 1
- Enrollment
- 20 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-08-06
Not yet recruitingNCT07745569
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
University of New Mexico
- Conditions
- PTSD · PTSD - Post Traumatic Stress Disorder · Major Depression · Suicidality
- Phase
- Phase 2
- Enrollment
- 150 estimated
- Locations
- No mapped site reported
- Registry updated
- 2026-08-04
Active, not recruitingNCT07336238
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression
University of Washington
- Conditions
- Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
- Phase
- Phase 2
- Enrollment
- 18 estimated
- Locations
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
- Registry updated
- 2026-07-31
Enrolling by invitationNCT07737990
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Joshua Rosenblat
- Conditions
- Treatment-resistant Depression (TRD)
- Phase
- Not applicable
- Enrollment
- 65 estimated
- Locations
- Toronto Western Hospital, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
RecruitingNCT06512220
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Centre for Addiction and Mental Health
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 12 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
RecruitingNCT06518720
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial
Centre for Addiction and Mental Health
- Conditions
- Treatment Resistant Depression · Chronic Pain
- Phase
- Phase 2
- Enrollment
- 16 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
RecruitingNCT06706232
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
The University of Texas Health Science Center, Houston
- Conditions
- Bipolar II Disorder · Depression, Bipolar · Suicidality
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- The University of Texas Health Science Center at Houston, Houston, Texas, United States
- Registry updated
- 2026-07-30
RecruitingNCT07211438
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial
Centre for Addiction and Mental Health
- Conditions
- Treatment-Resistant Depression
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- Toronto Western Hospital (University Health Network), Toronto, Ontario, Canada · Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-07-30
RecruitingNCT06200155
TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
- Conditions
- Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- MD Anderson Cancer Center, Houston, Texas, United States
- Registry updated
- 2026-07-29
RecruitingNCT06801041
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
- Conditions
- Depression · Anxiety · Cancer
- Phase
- Phase 2
- Enrollment
- 20 estimated
- Locations
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- Registry updated
- 2026-07-29
RecruitingNCT06355414
Psilocybin and Affective Function in Chronic Lower Back Pain Depression
Johns Hopkins University
- Conditions
- Chronic Low-back Pain · Depression
- Phase
- Phase 1
- Enrollment
- 40 estimated
- Locations
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Registry updated
- 2026-07-24
Active, not recruitingNCT06308653
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)
Usona Institute
- Conditions
- Depressive Disorder, Major
- Phase
- Phase 3
- Enrollment
- 238 actual
- Locations
- University of Alabama Clinical Research Unit, Birmingham, Alabama, United States · Preferred Research Partners-NWA, LLC, Fayetteville, Arkansas, United States · Preferred Research Partners, Inc., Little Rock, Arkansas, United States · +26 more
- Registry updated
- 2026-07-23
RecruitingNCT06820723
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
Ohio State University
- Conditions
- Depression · Anxiety · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- The Ohio State University Department of Psychiatry, Columbus, Ohio, United States
- Registry updated
- 2026-07-23
RecruitingNCT07610369
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Yale University
- Conditions
- Depression · Parkinson's Disease (PD)
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- Yale University, New Haven, Connecticut, United States
- Registry updated
- 2026-07-20
RecruitingNCT06247839
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sharmin Ghaznavi
- Conditions
- Major Depressive Disorder
- Phase
- Phase 3
- Enrollment
- 20 estimated
- Locations
- Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States
- Registry updated
- 2026-07-17
RecruitingNCT07703722
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial
Khyber Medical University Peshawar
- Conditions
- Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
- Phase
- Phase 3
- Enrollment
- 60 estimated
- Locations
- Institute of Health Science, Khyber Medical University, Islamabad, Capital, Pakistan · Hayatabad Medical Complex Peshawar, Peshawar, KPK, Pakistan · Khyber Medical University, Peshawar, KPK, Pakistan
- Registry updated
- 2026-07-14
Active, not recruitingNCT04754061
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial
Ottawa Hospital Research Institute
- Conditions
- Depression, Anxiety · Distress, Emotional
- Phase
- Phase 1 · Phase 2
- Enrollment
- 20 estimated
- Locations
- The Ottawa Hospital, Ottawa, Ontario, Canada · Bruyere Continuing Care, Ottawa, Ontario, Canada
- Registry updated
- 2026-07-10
Active, not recruitingNCT06341426
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)
University Health Network, Toronto
- Conditions
- Major Depressive Disorder · Depression · Treatment-Resistant Depression · Mood Disorders
- Phase
- Phase 2
- Enrollment
- 92 estimated
- Locations
- Toronto Western Hospital, Toronto, Ontario, Canada · Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
- Registry updated
- 2026-07-09
TerminatedNCT06624137
Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects
Yale University
- Conditions
- OCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer
- Phase
- Phase not reported
- Enrollment
- 5 actual
- Locations
- Connecticut Mental Health Center, Hamden, Connecticut, United States · West Haven VA Medical Center, West Haven, Connecticut, United States
- Registry updated
- 2026-07-09
RecruitingNCT07638553
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
Centre Hospitalier Universitaire de Nīmes
- Conditions
- Alcohol Use Disorder · Depressive Sympotoms · Psilocybin
- Phase
- Phase 3
- Enrollment
- 172 estimated
- Locations
- Centre Hospitalier de la Côte Basque, Bayonne, France · CHU Besançon, Besançon, France · CHU de Bordeaux, Bordeaux, France · +5 more
- Registry updated
- 2026-07-01
RecruitingNCT07104916
A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)
Anthony P King
- Conditions
- Post Traumatic Stress Disorder · Depression - Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- The Ohio State University Medical Center, Columbus, Ohio, United States
- Registry updated
- 2026-06-25
Not yet recruitingNCT07226232
A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans
VA Office of Research and Development
- Conditions
- Major Depression
- Phase
- Phase 3
- Enrollment
- 240 estimated
- Locations
- Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States · Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States · VA Portland Health Care System, Portland, OR, Portland, Oregon, United States · +2 more
- Registry updated
- 2026-06-05
CompletedNCT06230757
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial
University of Colorado, Denver
- Conditions
- Major Depressive Disorder · Anhedonia · Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 20 actual
- Locations
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Registry updated
- 2026-05-22
Not yet recruitingNCT07582120
A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression
Washington University School of Medicine
- Conditions
- Depression
- Phase
- Phase 2
- Enrollment
- 50 estimated
- Locations
- Washington University School of Medicine, St Louis, Missouri, United States
- Registry updated
- 2026-05-20
CompletedNCT05227612
Psilocybin-assisted Cognitive Behavioral Therapy for Depression
University of California, Los Angeles
- Conditions
- Major Depressive Disorder
- Phase
- Phase 1
- Enrollment
- 16 actual
- Locations
- UCLA Semel Institute, Los Angeles, California, United States
- Registry updated
- 2026-05-19
RecruitingNCT07216404
Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)
Alan Davis
- Conditions
- Lung Non-Small Cell Carcinoma · Unipolar Depression
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Registry updated
- 2026-05-14
RecruitingNCT06782724
The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.
University Medical Center Groningen
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease) · ALS (Amyotrophic Lateral Sclerosis) · MS (Multiple Sclerosis) · Major Depressive Disorder (MDD)
- Phase
- Phase 2
- Enrollment
- 108 estimated
- Locations
- National Institute of Mental Health, Prague, Czechia · Bispebjerg Hospital, Copenhagen, Denmark · University Medical Center Groningen, Groningen, Provincie Groningen, Netherlands · +1 more
- Registry updated
- 2026-05-08
CompletedNCT05710237
Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial
Centre for Addiction and Mental Health
- Conditions
- Treatment-resistant Depression
- Phase
- Phase 2
- Enrollment
- 41 actual
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-05-07
Active, not recruitingNCT05947383
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer
Sunstone Medical
- Conditions
- Cancer · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 56 estimated
- Locations
- Sunstone Medical, PC, Rockville, Maryland, United States
- Registry updated
- 2026-05-06
Active, not recruitingNCT06303739
Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study
University of North Carolina, Chapel Hill
- Conditions
- Refractory Depression · Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 20 actual
- Locations
- UNC Chapel Hill Medical Center, Chapel Hill, North Carolina, United States
- Registry updated
- 2026-05-06
Not yet recruitingNCT07479550
A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder
Stanford University
- Conditions
- Major Depression
- Phase
- Phase 2
- Enrollment
- 10 estimated
- Locations
- Stanford University, Stanford, California, United States
- Registry updated
- 2026-05-06
TerminatedNCT04353921
A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control
Usona Institute
- Conditions
- Major Depressive Disorder
- Phase
- Phase not reported
- Enrollment
- 26 actual
- Locations
- Innovative Clinical Research, Inc. (formerly Segal Trials), Lauderhill, Florida, United States
- Registry updated
- 2026-05-04
Not yet recruitingNCT07565909
A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression
University of Washington
- Conditions
- Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 72 estimated
- Locations
- No mapped site reported
- Registry updated
- 2026-05-04
RecruitingNCT07251491
Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury
James J. Peters Veterans Affairs Medical Center
- Conditions
- Spinal Cord Injury · Depression - Major Depressive Disorder · Veteran
- Phase
- Phase 1 · Phase 2
- Enrollment
- 30 estimated
- Locations
- James J. Peters Department of Veterans Affairs Medical Center, The Bronx, New York, United States
- Registry updated
- 2026-05-04
Not yet recruitingNCT07566104
Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder
University of California, Los Angeles
- Conditions
- Depression - Major Depressive Disorder · Psilocybin · Cognitive Behavioral Therapy
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- UCLA Semel Institute, Los Angeles, California, United States
- Registry updated
- 2026-05-04
Not yet recruitingNCT06943573
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial
Lakshmi N Yatham
- Conditions
- Bipolar II Depression
- Phase
- Phase 3
- Enrollment
- 90 estimated
- Locations
- Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada · Department of Psychiatry, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada · Department of Psychiatry, University of Toronto, University Health Network,, Toronto, Ontario, Canada
- Registry updated
- 2026-05-01
RecruitingNCT05883540
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)
University Hospital, Basel, Switzerland
- Conditions
- Palliative Care · Pain · Anxiety · Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland · University Hospital Geneva, Palliative medicine department, Collonge-Bellerive, Switzerland · Spital Uster AG, Division of Internal Medicine, Uster, Switzerland · +1 more
- Registry updated
- 2026-04-29
CompletedNCT03866174
A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
Usona Institute
- Conditions
- Depressive Disorder, Major
- Phase
- Phase 2
- Enrollment
- 347 actual
- Locations
- University of California, San Francisco, San Francisco, California, United States · Pacific Neuroscience Institute, Santa Monica, California, United States · Yale University, New Haven, Connecticut, United States · +8 more
- Registry updated
- 2026-04-22
Not yet recruitingNCT07373535
Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy
Kyle Greenway
- Conditions
- Treatment-Resistant Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 16 estimated
- Locations
- Jewish General Hospital, Montreal, Quebec, Canada
- Registry updated
- 2026-04-22
RecruitingNCT06072898
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression
Sunnybrook Health Sciences Centre
- Conditions
- Depressive Disorder · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 50 estimated
- Locations
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Registry updated
- 2026-03-30
Not yet recruitingNCT07499583
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
Indiana University
- Conditions
- Treatment Resistant Depression · Substance Use Disorders
- Phase
- Phase 1 · Phase 2
- Enrollment
- 50 estimated
- Locations
- Goodman Hall, Dept of Psychiatry, Indiana University, Indianapolis, Indiana, United States · The Stark Neuroscience Building (Goodman Hall), Indianapolis, Indiana, United States
- Registry updated
- 2026-03-30
RecruitingNCT06898606
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression
Federal University of Latin American Integration
- Conditions
- Depressive Disorder
- Phase
- Phase 1 · Phase 2
- Enrollment
- 24 estimated
- Locations
- Federal University of Latin American Integration, Foz do Iguaçu, Paraná, Brazil
- Registry updated
- 2026-03-27
RecruitingNCT07490353
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial
Medical University of Vienna
- Conditions
- Depression - Major Depressive Disorder · Anhedonia
- Phase
- Phase 1
- Enrollment
- 85 estimated
- Locations
- Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Vienna, State of Vienna, Austria
- Registry updated
- 2026-03-24
RecruitingNCT04123314
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease
Johns Hopkins University
- Conditions
- Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment
- Phase
- Early Phase 1
- Enrollment
- 20 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-03-16
Active, not recruitingNCT04620759
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
- Conditions
- Major Depressive Disorder · Alcohol Use Disorder
- Phase
- Phase 2
- Enrollment
- 90 estimated
- Locations
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
- Registry updated
- 2026-03-13
RecruitingNCT06442423
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
Yale University
- Conditions
- Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms
- Phase
- Phase 1
- Enrollment
- 50 estimated
- Locations
- Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut, United States
- Registry updated
- 2026-03-11
Not yet recruitingNCT07405606
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial
Centre for Addiction and Mental Health
- Conditions
- Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD)
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Registry updated
- 2026-02-12
RecruitingNCT07281352
Psilocybin-Assisted Cognitive Behavioral Therapy for Depression
University of California, Los Angeles
- Conditions
- Major Depressive Diorder
- Phase
- Phase 1 · Phase 2
- Enrollment
- 50 estimated
- Locations
- UCLA Semel Institute, Los Angeles, California, United States
- Registry updated
- 2026-02-12
Active, not recruitingNCT05711940
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 572 actual
- Locations
- Lighthouse Psychiatry Scottsdale, Gilbert, Arizona, United States · Clinical Innovations, Inc., Bellflower, California, United States · M3 Wake Research, Encino, California, United States · +113 more
- Registry updated
- 2026-01-12
CompletedNCT05259943
Microdosing Psychedelics to Improve Mood
Rotem Petranker
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 39 actual
- Locations
- Psych Research, Toronto, Ontario, Canada
- Registry updated
- 2025-12-30
CompletedNCT05220410
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Sheppard Pratt Health System
- Conditions
- Treatment Resistant Depression · Suicidal Ideation
- Phase
- Phase 2
- Enrollment
- 20 actual
- Locations
- Sheppard Pratt Health System, Baltimore, Maryland, United States
- Registry updated
- 2025-12-24
CompletedNCT05399498
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
University of Chicago
- Conditions
- Borderline Personality Disorder · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 9 actual
- Locations
- University of Chicago, Chicago, Illinois, United States
- Registry updated
- 2025-12-23
Active, not recruitingNCT05624268
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 3
- Enrollment
- 255 estimated
- Locations
- University of Arizona College of Medicine - Tuscon, Tucson, Arizona, United States · ProScience Research Group, Culver City, California, United States · Collaborative Neuroscience Network, LLC, Garden Grove, California, United States · +37 more
- Registry updated
- 2025-12-18
RecruitingNCT06132178
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder
University of Texas at Austin
- Conditions
- Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression
- Phase
- Phase 2
- Enrollment
- 100 estimated
- Locations
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas, United States
- Registry updated
- 2025-11-26
RecruitingNCT07183748
A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression
Beersheva Mental Health Center
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 20 estimated
- Locations
- Mental Health Center Beer Sheva, Beersheba, Israel
- Registry updated
- 2025-11-19
Active, not recruitingNCT03554174
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Yale University
- Conditions
- Major Depressive Disorder
- Phase
- Phase 1
- Enrollment
- 18 estimated
- Locations
- VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut, United States
- Registry updated
- 2025-11-05
Not yet recruitingNCT07210112
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Centre Hospitalier St Anne
- Conditions
- Depression - Major Depressive Disorder · Treatment-resistant Depression (TRD)
- Phase
- Phase 2
- Enrollment
- 112 estimated
- Locations
- GHU Paris Psychiatrie and Neurosciences, Paris, France
- Registry updated
- 2025-10-07
Active, not recruitingNCT07164287
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
University Hospital, Geneva
- Conditions
- Major Depressive Disorder (MDD) · Anxiety Disorders · Substance Use Disorder (SUD) · PTSD - Post Traumatic Stress Disorder
- Phase
- Phase not reported
- Enrollment
- 376 estimated
- Locations
- Geneva University Hospital, Geneva, Switzerland
- Registry updated
- 2025-10-02
Active, not recruitingNCT07164755
Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.
King's College London
- Conditions
- Depression - Major Depressive Disorder
- Phase
- Phase not reported
- Enrollment
- 46 actual
- Locations
- King's College London Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
- Registry updated
- 2025-09-10
RecruitingNCT06899165
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy
Rachel Yehuda
- Conditions
- Psychological Stress · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 100 estimated
- Locations
- The Parsons Research Center for Psychedelic Healing, New York, New York, United States
- Registry updated
- 2025-09-08
CompletedNCT06746441
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial
Khyber Medical University Peshawar
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 60 actual
- Locations
- Lady Reading Hospital, Pakistan, Peshawar, Khyber Pakhtunkhwa, Pakistan
- Registry updated
- 2025-09-02
CompletedNCT06650800
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study
Centre Hospitalier Universitaire de Nīmes
- Conditions
- Depressive Disorder · Depressive Disorder, Treatment-Resistant · Hallucinogens · Reinforcement, Psychology
- Phase
- Not applicable
- Enrollment
- 10 actual
- Locations
- CHU de Nîmes, Hôpital Universitaire Carémeau, Nîmes, France
- Registry updated
- 2025-08-20
Active, not recruitingNCT05733546
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
COMPASS Pathways
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 102 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States · Sunstone Therapies, Rockville, Maryland, United States · +2 more
- Registry updated
- 2025-08-19
CompletedNCT06372197
Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study
Matthew Hicks
- Conditions
- Depression
- Phase
- Not applicable
- Enrollment
- 20 actual
- Locations
- National University of Natural Medicine, Portland, Oregon, United States
- Registry updated
- 2025-06-05
RecruitingNCT06512194
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)
Charles Raison
- Conditions
- Depression
- Phase
- Phase 2
- Enrollment
- 141 estimated
- Locations
- Vail Health Behavioral Health, Edwards, Colorado, United States
- Registry updated
- 2025-05-23
RecruitingNCT06592833
Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder
Icahn School of Medicine at Mount Sinai
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York, United States
- Registry updated
- 2025-05-14
CompletedNCT05581797
Psilocybin-assisted Interpersonal Therapy for Depression
University of Otago
- Conditions
- Depressive Disorder, Treatment-Resistant
- Phase
- Not applicable
- Enrollment
- 5 actual
- Locations
- University of Otago, Christchurch, New Zealand
- Registry updated
- 2025-04-09
CompletedNCT06235411
Psilocybin in Alcohol Use Disorder With Comorbid Depression
Centre Hospitalier Universitaire de Nīmes
- Conditions
- Alcohol-Related Disorders · Depressive Disorder · Addiction
- Phase
- Not applicable
- Enrollment
- 30 actual
- Locations
- CHU, Nîmes, Nîmes, France
- Registry updated
- 2025-03-19
CompletedNCT05163496
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout
University of Washington
- Conditions
- Burnout, Caregiver · Burnout, Professional · COVID-19 · Depression
- Phase
- Phase 3
- Enrollment
- 30 actual
- Locations
- University of Washington, Seattle, Washington, United States
- Registry updated
- 2025-03-18
CompletedNCT04670081
A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression
Central Institute of Mental Health, Mannheim
- Conditions
- Treatment-resistant Depression
- Phase
- Phase 2
- Enrollment
- 144 actual
- Locations
- Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy, Berlin, Germany · Central Institute of Mental Health (CIMH), Mannheim, Germany
- Registry updated
- 2025-01-20
CompletedNCT04932434
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
Joshua Woolley, MD, PhD
- Conditions
- Parkinson Disease · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 12 actual
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2025-01-01
CompletedNCT05557643
PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout
University of Utah
- Conditions
- Depression · Burnout, Professional
- Phase
- Phase 1
- Enrollment
- 24 actual
- Locations
- Huntsman Mental Health Institute, Salt Lake City, Utah, United States
- Registry updated
- 2024-11-12
CompletedNCT03429075
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
Imperial College London
- Conditions
- Depressive Disorder, Major
- Phase
- Phase 2
- Enrollment
- 59 actual
- Locations
- Imperial College Hammersmith campus, London, United Kingdom
- Registry updated
- 2024-10-24
RecruitingNCT06506019
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study
University Health Network, Toronto
- Conditions
- Bipolar Depression
- Phase
- Phase 1
- Enrollment
- 30 estimated
- Locations
- Toronto Western Hospital - University Health Network, Toronto, Ontario, Canada
- Registry updated
- 2024-10-18
RecruitingNCT06378229
Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus
University Hospital, Ghent
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 100 estimated
- Locations
- Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium
- Registry updated
- 2024-09-19
Active, not recruitingNCT04433858
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sheppard Pratt Health System
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 27 actual
- Locations
- VA Palo Alto Healthcare System/Stanford Medicine, Palo Alto, California, United States · Sheppard Pratt Health System, Baltimore, Maryland, United States
- Registry updated
- 2024-08-09
WithdrawnNCT05675800
Psilocybin for the Treatment of Major Depressive Disorder
Washington University School of Medicine
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- No mapped site reported
- Registry updated
- 2024-07-25
Unknown statusNCT06444243
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder
University of Sydney
- Conditions
- Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 90 estimated
- Locations
- No mapped site reported
- Registry updated
- 2024-06-10
CompletedNCT04630964
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study
Section for Affective Disorders; Northern Stockholm Psychiatry
- Conditions
- Major Depressive Disorder · Depression
- Phase
- Phase 2
- Enrollment
- 35 actual
- Locations
- Northern Stockholm Spychiatry Clinic, Stockholm, Sweden
- Registry updated
- 2024-04-19
WithdrawnNCT05381974
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
Massachusetts General Hospital
- Conditions
- Treatment-Resistant Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States
- Registry updated
- 2024-01-24
Unknown statusNCT06141876
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).
Apex Labs Ltd.
- Conditions
- Post-traumatic Stress Disorder · Depression
- Phase
- Phase 2
- Enrollment
- 160 estimated
- Locations
- No mapped site reported
- Registry updated
- 2023-11-29
CompletedNCT04739865
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 19 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Sheaf House, Tallaght Hospital, Dublin, Ireland
- Registry updated
- 2023-11-09
CompletedNCT05029466
The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study
Brain and Cognition Discovery Foundation
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 30 actual
- Locations
- Canadian Rapid Treatment Centre of Excellence (CRTCE), Mississauga, Ontario, Canada
- Registry updated
- 2023-07-27
WithdrawnNCT05594667
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)
Cybin Therapeutics Inc.
- Conditions
- Depression · Major Depressive Disorder · Mild Depression · Moderate Depression
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Centre for Neurology Studies x Upstream, Abbotsford British Columbia, British Columbia, Canada
- Registry updated
- 2023-07-06
CompletedNCT03775200
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 233 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States · Stanford Department of Psychiatry, Stanford, California, United States · +22 more
- Registry updated
- 2023-04-24
WithdrawnNCT05601648
SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression
Washington University School of Medicine
- Conditions
- Major Depressive Disorder · Anhedonia
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Washington University School of Medicine, St Louis, Missouri, United States
- Registry updated
- 2023-01-30
Unknown statusNCT04433845
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Sheppard Pratt Health System
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 15 actual
- Locations
- Sheppard Pratt, Baltimore, Maryland, United States
- Registry updated
- 2022-10-25
CompletedNCT04519957
Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)
COMPASS Pathways
- Conditions
- Treatment Resistant Depression
- Phase
- Phase not reported
- Enrollment
- 66 actual
- Locations
- Kadima Neuropsychiatry Institute, La Jolla, California, United States · Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States · Mood and Anxiety Disorders Program Emory University School of Medicine, Atlanta, Georgia, United States · +5 more
- Registry updated
- 2022-09-22
WithdrawnNCT04989972
Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults
Wake Network, Inc.
- Conditions
- Anxiety and Depression
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- FMS Department of Psychiatry, Kingston, Jamaica
- Registry updated
- 2022-06-30
Unknown statusNCT05383313
Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression
National Institute of Mental Health, Czech Republic
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- National Institute of Mental Health, Klecany, Czechia
- Registry updated
- 2022-05-20
CompletedNCT03715127
Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression
University of Zurich
- Conditions
- Depressive Disorder, Major
- Phase
- Phase 2
- Enrollment
- 55 actual
- Locations
- Psychiatrische Universitätsklinik Zürich, Zurich, Switzerland
- Registry updated
- 2022-04-29
CompletedNCT03181529
Effects of Psilocybin in Major Depressive Disorder
Johns Hopkins University
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 27 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
- Registry updated
- 2021-12-15
Unknown statusNCT04593563
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
Maryland Oncology Hematology, PA
- Conditions
- Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 30 actual
- Locations
- Maryland Oncology Hematology PA, Rockville, Maryland, United States
- Registry updated
- 2021-10-15
Unknown statusNCT04959253
A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study
King's College London
- Conditions
- Treatment Resistant Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- Clinical Research Facility, King's College Hospital, London, United Kingdom
- Registry updated
- 2021-07-22
CompletedNCT02950467
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
Joshua Woolley
- Conditions
- Distress · Depression · Grief
- Phase
- Phase 1
- Enrollment
- 30 actual
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2021-01-07
CompletedNCT00465595
Psychopharmacology of Psilocybin in Cancer Patients
Johns Hopkins University
- Conditions
- Depressive Symptoms · Anxiety · Cancer
- Phase
- Phase 2
- Enrollment
- 56 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States
- Registry updated
- 2018-07-19
Unknown statusNCT03380442
Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression
University of Helsinki
- Conditions
- Severe Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- No mapped site reported
- Registry updated
- 2017-12-21
Related research views
Continue exploring clinical trials
Move between curated condition, country, phase, and recruiting views without losing direct source provenance.
Recruitment
Conditions
Countries
Phases
Method and accountability
How this collection is maintained
Automatic refresh: counts, facets, records, and the map update from the tracker after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.
Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.
Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.